Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.22p -6.47% 3.18p 4,001,062 16:35:04
Bid Price Offer Price High Price Low Price Open Price
3.10p 3.30p 3.40p 3.20p 3.40p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.02 -1.97 -0.49 14.7

Nuformix (NFX) Latest News

More Nuformix News
Nuformix Takeover Rumours

Nuformix (NFX) Share Charts

1 Year Nuformix Chart

1 Year Nuformix Chart

1 Month Nuformix Chart

1 Month Nuformix Chart

Intraday Nuformix Chart

Intraday Nuformix Chart

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
19/4/201910:47Nuformix plc417

Add a New Thread

Nuformix (NFX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

Nuformix Daily Update: Nuformix is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 3.40p.
Nuformix has a 4 week average price of 2.15p and a 12 week average price of 1.93p.
The 1 year high share price is 4.40p while the 1 year low share price is currently 1.60p.
There are currently 460,750,000 shares in issue and the average daily traded volume is 8,397,665 shares. The market capitalisation of Nuformix is £14,651,850.
researchanalyst1: PROFOUNDLY UNDERVALUED... So, has the market got it? Has the market realised that Nuformix is now a first mover in the multibillion dollar, Canadian cannabinoid market? That it stands to receive, shortly, a significant upfront payment running into the millions? And that the payment is likely to dwarf its current market cap? Answer: definitely not. The share price at sub-10p underpins a gross lack of understanding of the transformational nature of the RNS. To this end, take cue from the savvy investors picking-up stock at these obscene levels. A further RNS outlining the significant upfront payment is now imminent. Remember, the projected Canadian consumer market for cannabinoid-based pharmaceuticals in 2020 alone is in excess of £2bn! Nuformix, through Ebers, is now a first mover in this market. Https:// Https://
soupdragon55: Possible Near Term Share Price Catalyst We expect news on an out-licensing deal quite shortly, which could further validate NFX’s cocrystal technology and the progress made with this to date. In addition, we look for a boost to near and medium term income, which could allow NFX to progress further with the development of its other products.
rathean: Resistance at 4p, if we finish above could see a good few pennies added to the share price. Great RNS, opens up a huge market in addition to other formulas being licensed for recurring revenues.
natty27: Simpleton.... very apt name considering! I'm actually invested in nfx you donut!, & it's clear to see if you re-read my post again that I'm not de-ramping a company that I'm invested in. All I was saying is I expect to see a bit of consolidation before moving on to new highs. As you should know... we need to back test our highs before moving on again. I'm sure you would, along with me see the share price on a gradual trend upwards over the next couple of weeks/months/years, rather than sharp increase, followed by sharp declines, as the overused phase goes, nothing goes up in straight lines! Next time you might be less sensitive on trying to pull up a fellow investor in the same company! Not be the can't take any criticism crew, only that everything is amazing & this is going to £1 by the end of the week, boom, to the moon, rockets & fireworks crew!
Nuformix share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190421 20:54:24